These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

669 related articles for article (PubMed ID: 26514978)

  • 1. Change in autoantibody and cytokine responses during the evolution of neuromyelitis optica in patients with systemic lupus erythematosus: A preliminary study.
    Kovacs KT; Kalluri SR; Boza-Serrano A; Deierborg T; Csepany T; Simo M; Rokusz L; Miseta A; Alcaraz N; Czirjak L; Berki T; Molnar T; Hemmer B; Illes Z
    Mult Scler; 2016 Aug; 22(9):1192-201. PubMed ID: 26514978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders.
    Mader S; Gredler V; Schanda K; Rostasy K; Dujmovic I; Pfaller K; Lutterotti A; Jarius S; Di Pauli F; Kuenz B; Ehling R; Hegen H; Deisenhammer F; Aboul-Enein F; Storch MK; Koson P; Drulovic J; Kristoferitsch W; Berger T; Reindl M
    J Neuroinflammation; 2011 Dec; 8():184. PubMed ID: 22204662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
    Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
    J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
    J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica.
    Rostásy K; Mader S; Hennes EM; Schanda K; Gredler V; Guenther A; Blaschek A; Korenke C; Pritsch M; Pohl D; Maier O; Kuchukhidze G; Brunner-Krainz M; Berger T; Reindl M
    Mult Scler; 2013 Jul; 19(8):1052-9. PubMed ID: 23257621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
    Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
    JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica.
    Mader S; Lutterotti A; Di Pauli F; Kuenz B; Schanda K; Aboul-Enein F; Khalil M; Storch MK; Jarius S; Kristoferitsch W; Berger T; Reindl M
    PLoS One; 2010 May; 5(5):e10455. PubMed ID: 20463974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoglobulin M antibodies to aquaporin-4 in neuromyelitis optica and related disorders.
    Jarius S; Franciotta D; Bergamaschi R; Wildemann B; Wandinger KP
    Clin Chem Lab Med; 2010 May; 48(5):659-63. PubMed ID: 20184532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolated new onset 'atypical' optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up.
    Piccolo L; Woodhall M; Tackley G; Juryńczyk M; Kong Y; Domingos J; Gore R; Vincent A; Waters P; Leite MI; Palace J
    J Neurol; 2016 Feb; 263(2):370-379. PubMed ID: 26668077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative measurement of anti-aquaporin-4 antibodies by enzyme-linked immunosorbent assay using purified recombinant human aquaporin-4.
    Kim W; Lee JE; Li XF; Kim SH; Han BG; Lee BI; Kim JK; Choi K; Kim HJ
    Mult Scler; 2012 May; 18(5):578-86. PubMed ID: 21965418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells.
    Hinson SR; McKeon A; Fryer JP; Apiwattanakul M; Lennon VA; Pittock SJ
    Arch Neurol; 2009 Sep; 66(9):1164-7. PubMed ID: 19752309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Semiquantitative measurement of aquaporin-4 antibodies as a possible surrogate marker of neuromyelitis optica spectrum disorders with systemic autoimmune diseases.
    Katsumata Y; Kawachi I; Kawaguchi Y; Gono T; Ichida H; Hara M; Yamanaka H
    Mod Rheumatol; 2012 Sep; 22(5):676-84. PubMed ID: 22183613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiacquaporin 4 antibodies detection by different techniques in neuromyelitis optica patients.
    Fazio R; Malosio ML; Lampasona V; De Feo D; Privitera D; Marnetto F; Centonze D; Ghezzi A; Comi G; Furlan R; Martino G
    Mult Scler; 2009 Oct; 15(10):1153-63. PubMed ID: 19667009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre.
    Takahashi T; Fujihara K; Nakashima I; Misu T; Miyazawa I; Nakamura M; Watanabe S; Shiga Y; Kanaoka C; Fujimori J; Sato S; Itoyama Y
    Brain; 2007 May; 130(Pt 5):1235-43. PubMed ID: 17449477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers for neuromyelitis optica.
    Chang KH; Ro LS; Lyu RK; Chen CM
    Clin Chim Acta; 2015 Feb; 440():64-71. PubMed ID: 25444748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica.
    Jarius S; Aboul-Enein F; Waters P; Kuenz B; Hauser A; Berger T; Lang W; Reindl M; Vincent A; Kristoferitsch W
    Brain; 2008 Nov; 131(Pt 11):3072-80. PubMed ID: 18945724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aquaporin-4-autoimmunity in patients with systemic lupus erythematosus: A predominantly population-based study.
    Asgari N; Jarius S; Laustrup H; Skejoe HP; Lillevang ST; Weinshenker BG; Voss A
    Mult Scler; 2018 Mar; 24(3):331-339. PubMed ID: 28326889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification and functional characterization of antibodies to native aquaporin 4 in neuromyelitis optica.
    Kalluri SR; Illes Z; Srivastava R; Cree B; Menge T; Bennett JL; Berthele A; Hemmer B
    Arch Neurol; 2010 Oct; 67(10):1201-8. PubMed ID: 20937947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica.
    Takahashi T; Fujihara K; Nakashima I; Misu T; Miyazawa I; Nakamura M; Watanabe S; Ishii N; Itoyama Y
    Tohoku J Exp Med; 2006 Dec; 210(4):307-13. PubMed ID: 17146196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency of autoimmune disorders and autoantibodies in patients with neuromyelitis optica.
    Pereira WLCJ; Reiche EMV; Kallaur AP; Oliveira SR; Simão ANC; Lozovoy MAB; Schiavão LJV; Rodrigues PRDVP; Alfieri DF; Flauzino T; Kaimen-Maciel DR
    Acta Neuropsychiatr; 2017 Jun; 29(3):170-178. PubMed ID: 27692000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.